Marketers of "Facilitated Communication" Devices
Agree to Settle FTC Charges

FTC News Release
December 15, 1994

Two companies that market communication devices for autistic or other developmentally-disabled individuals with severe communication disabilities have agreed to settle Federal Trade Commission charges that they made false and unsubstantiated claims that the devices enable such individuals to communicate through the process of "facilitated communication." The devices at issue are similar to a typewriter, computer, or other alphabet display chart, and cost from $130 to $1,100. In separate proposed settlements, the companies would be prohibited from making false or unsubstantiated performance claims about any communication aid they offer in the future.

Facilitated communication is a process by which an assistant or facilitator provides physical support, such as wrist or hand holding, to a disabled person to "help" the person type or point to letters on a keyboard.

In separate cases, the Commission named Louis Bass, Inc., doing business as Crestwood Company; and Abovo, Inc., and its president, Susan Lakso. Crestwood, based in Glendale, WI, sells its devices — the "Crestalk" and the "Canon Communicator" — through its catalog, published twice a year. Abovo, based in Chicopee, MA, markets the "Abovo Personal Communicating Device (Abovo PCD)," through print ads and promotional video.

In its complaints detailing the charges, the FTC alleged that the respondents used advertisements that contained false and unsubstantiated representations concerning the efficacy of their communication devices in enabling individuals with disabilities to communicate through facilitated communication. Specifically, the FTC alleged that Crestwood claimed in its advertisements that the Crestalk and Canon Communicator will enable autistic individuals to communicate through facilitated communication. Similarly, the Commission alleged that Abovo's advertisements specifically claimed that the Abovo PCD enables autistic and mentally retarded individuals to communicate through facilitated communication. These claims are both false and unsubstantiated, according to the FTC.

The FTC also alleged that Abovo did not have adequate and reliable substantiation for its claim that the Abovo PCD enables individuals who are disabled as a result of apraxia, motor speech disorders, laryngeal cancer, cerebral palsy, multiple sclerosis, stroke, Alzheimer's disease or other named disorders, to communicate through facilitated communication.

The proposed consent agreements to settle the charges, announced today for public comment, would prohibit the Crestwood and Abovo respondents from misrepresenting that any communication aid will assist autistic and/or mentally retarded individuals to communicate through facilitated communication.

In addition, the proposed settlements would prohibit the respondents from making representations about the ability of any communication aid to assist an individual with a disability to communicate through facilitated communication, unless the representation is true and the respondents have competent and reliable scientific evidence to substantiate the representation.

Finally, the proposed settlements include various reporting requirements that would assist the FTC in monitoring the respondents' compliance with their provisions.

The Commission vote to approve the proposed consent agreements for public comment was 3-0, with Commissioner Mary L. Azcuenaga recused. The FTC's San Francisco Regional Office handled the investigations.

Related Documents

This page was posted on August 27, 2006.

Links to Recommended Companies

  • Compare drug prices and save money at verified online pharmacies.
  • Evaluates the quality of dietary supplement and herbal products.
  • Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.